Skip to content

Stock-Based Comp at other companies

Plexus logo
PlexusPLXS

Other financials

Income statement

See full
Revenue$13.0K+8.3%
Gross profit$12.0K-88.9%
Operating income-$35.7M-1,098%
Net income-$46.7M-1,560%
EPS (diluted)-$0.27-92.9%

Balance sheet

See full
Cash & equivalents$6.9M+84.0%
Total debt$15.0K-94.7%
Total equity$159.0M+6,003%
Total assets$173.3M+3,823%

Cash flow

See full
Operating cash flow-$10.2M-813%
CapEx$4.0K-93.1%
Free cash flow-$2.9M+29.4%

Valuation

See full
Market cap$88.66M-56.4%
P/S2,216.6×-5,967×

Profitability

See full
Gross margin80.1%+25.2pp
Operating margin-32,155%-14,261pp
Net margin-25,825%-11,789pp
FCF margin-97,216.7%-106,293pp

Returns & leverage

See full
Return on equity-627.1%
Debt / equity
Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioSig Technologies, Inc.'s stock-based comp?
BioSig Technologies, Inc. (STEX) reported stock-based comp of $25.37M in Q1 2026.
How has BioSig Technologies, Inc.'s stock-based comp changed year-over-year?
BioSig Technologies, Inc.'s stock-based comp increased by 1123.2% year-over-year, from $2.07M to $25.37M.
What is the long-term trend for BioSig Technologies, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), BioSig Technologies, Inc.'s stock-based comp has grown at a 56.6% compound annual growth rate (CAGR), from $9.5M to $57.1M.